Discover
SPRO
Spero Therapeutics, Inc.
2.22
2 x 1.63
2 x 2.86
bid
ask
+
0.01
0.45%
2 @ 04:00 PM
2.25 +0.03 (1.36%)
| Ytd | -4.72% | |
| 1y | -23.45% |
2.21
day range
2.27
1.80
52 week range
3.22
| Open | 2.21 | Prev Close | 2.21 | Low | 2.21 | High | 2.27 | Mkt Cap | 128.54M |
| Vol | 381.12K | Avg Vol | 993.50K | EPS | 0.27 | P/E | 8.22 | Forward P/E | -0.83 |
| Beta | 0.63 | Short Ratio | 2.08 | Inst. Own | 23.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 2.59 | 200-d Avg | 2.41 | 1yr Est | 5.00 |
SPRO News
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premark
Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs
FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
GSK, Spero Therapeutics Announce FDA Approves Utebzi To Treat Complicated Urinary Tract Infections
https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adult